PremiumRatingsLegend Biotech: Strong Sales and Strategic Focus Drive Buy Rating Legend Biotech’s Strong CARVYKTI Sales Outlook and Capacity Expansion Drive Buy Rating Legend Biotech price target raised to $75 from $73 at H.C. Wainwright PremiumThe FlyLegend Biotech sees cash runway into 2Q26 Legend Biotech Corporation (LEGN) Q4 Earnings Cheat Sheet Positive Developments in Carvykti Therapy Propel Legend Biotech to ‘Buy’ Rating PremiumThe FlyLegend Biotech price target lowered to $84 from $86 at RBC Capital Piper lowers sales estimates for Legend Biotech’s Carvykti Legend Biotech Announces Employee Transition Agreement